Governance Guidance for Biopharma Board Members
Experience-based counsel for the people who sit in the boardroom and make the decisions. Not theory. Not checklists. The real work of governing clinical-stage companies.
Read the LatestWhat We Cover
Governance Fundamentals
The foundational knowledge that generic governance resources don't teach
Browse →Clinical-Stage Decision Making
The board's role in the decisions that define clinical-stage companies
Browse →Capital & Strategic Transactions
Financial governance, fundraising oversight, and exit preparation
Browse →Board Dynamics & Effectiveness
The human and organizational dimensions of board governance
Browse →Recent Articles
Reading a Clinical Trial Protocol as a Board Member
A clinical trial protocol is the document in which a program's fate is largely already decided. Most directors never read one, and don't need to read it like a scientist. But knowing where to look — and what a handful of choices commit the company to — is one of the highest-leverage skills a clinical-stage director can have.
Compassionate Use: Governing the Decision No One Wants to Make Wrongly
A dying patient wants a company's investigational drug. The request is human, urgent, and hard to refuse — and the decision carries clinical, ethical, operational, and development consequences that a board should ensure the company has thought through before the first request arrives, not after.
Biomarker-Driven Development: What Boards Need to Understand About Betting on a Signal
A biomarker strategy can transform a program's odds — a smaller, faster, more likely-to-succeed trial in the patients most likely to respond. It also introduces a second development program, a second regulatory relationship, and a set of risks boards routinely underestimate.
Stay Informed
A weekly newsletter with governance insights, case studies, and analysis for biopharma board members.
No spam. Unsubscribe anytime.